Biotech

News

BiVictriX's chief executive Tiffany Thorn

Another AIM defection as BiVictriX plans to delist

The list of UK biotechs deciding to abandon listings on the AIM exchange in the UK just lengthened, after BiVictriX said it wants to cancel its shares and go private.

News

Biopharma, finance vets launch $600m life sciences loan firm

There's a new source of funding for life sciences companies in town, providing credit as an alternative to other financing avenues such as venture capital.

News

FibroGen scientist records data manually into a notebook

FibroGen wields axe as pancreatic cancer drug is canned

FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce.

News

Third Arc's $165m for T cell engagers, plus other bio rounds

This week's round-up of new financings in the biotech world is headed by a big round for Third Arc, a specialist in T-cell engager antibodies, with Autobahn, Brenig, Confo, and GRO Bio also

News

Cardurion heads crop of sizeable bio financings

While the pace of biotech private rounds seems to have slowed a little of late, this week saw four big financings for Cardurion Pharma, Scorpion Therapeutics, CatalYm, and NGM Bio.

News

Re-elected von der Leyen pledges EU measures for biotech

Ursula von der Leyen has been re-elected as president of the European Commission following a secret ballot in the European Parliament and, among the pledges made during her speech before th

Another AIM defection as BiVictriX plans to delist

Biopharma, finance vets launch $600m life sciences loan firm

FibroGen wields axe as pancreatic cancer drug is canned

Third Arc's $165m for T cell engagers, plus other bio rounds

Cardurion heads crop of sizeable bio financings

Re-elected von der Leyen pledges EU measures for biotech

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Biotech

Editor's Picks